Literature DB >> 27839542

In Reply.

Adrian Gillissen1.   

Abstract

Year:  2016        PMID： 27839542      PMCID： PMC5143801          DOI： 10.3238/arztebl.2016.0692b

Source DB:  PubMed          Journal:  Dtsch Arztebl Int        ISSN： 1866-0452            Impact factor:   5.594


× No keyword cloud information.
  3 in total

1.  Roflumilast with long-acting β2-agonists for COPD: influence of exacerbation history.

Authors:  E D Bateman; K F Rabe; P M A Calverley; U M Goehring; M Brose; D Bredenbröker; L M Fabbri
Journal:  Eur Respir J       Date:  2011-07-07       Impact factor: 16.671

2.  Effect of roflumilast on exacerbations in patients with severe chronic obstructive pulmonary disease uncontrolled by combination therapy (REACT): a multicentre randomised controlled trial.

Authors:  Fernando J Martinez; Peter M A Calverley; Udo-Michael Goehring; Manja Brose; Leonardo M Fabbri; Klaus F Rabe
Journal:  Lancet       Date:  2015-02-13       Impact factor: 79.321

Review 3.  The Pharmacological Treatment of Chronic Obstructive Pulmonary Disease.

Authors:  Adrian Gillissen; Peter Haidl; Martin Khlhäufl; Klaus Kroegel; Thomas Voshaar; Christian Gessner
Journal:  Dtsch Arztebl Int       Date:  2016-05-06       Impact factor: 5.594
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.